The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event. METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined by an upper boundary of the 95% confidence interval for the hazard ratio of less than 1.3 and 1.0, respectively, for the primary composite end point of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: The 6068 patients who underwent randomization were followed for a median of 25 months. A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of lixisenatide to placebo (P<0.001) but did not show superiority (P=0.81). There were no significant between-group differences in the rate of hospitalization for heart failure (hazard ratio in the lixisenatide group, 0.96; 95% CI, 0.75 to 1.23) or the rate of death (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Lixisenatide was not associated with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions than was placebo. CONCLUSIONS: In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial,14 the GLP-1–receptor agonist lixisenatide, which is shorter-acting than and structurally dissimilar to liraglutide, did not show any cardiovascular benefit in patients with diabetes and a recent acute coronary syndrome.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“No increased risk of heart failure hospitalization has been identified in the cardiovascular outcomes trials of the GLP-1 RAs lixisenatide, liraglutide, semaglutide, exenatide once weekly, albiglutide, or dulaglutide compared with placebo (261,264,265,296,297).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [297]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [641]
Experimental — accuracy not yet measuredIn the citing paper
“The study showed that lixisenatide is not inferior, although not superior, to placebo in cardiovascular safety.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [55]
In the citing paper
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [61]
In the citing paper
“In the ELIXA trial, lixisenatide 10 or 20 μg o.d. was non-inferior to placebo, but did not significantly affect a four-point MACE (three-point MACE plus hospitalization for unstable angina) in patients with T2DM post-ACS.158”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF. 70,158-164,545 IIa A”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) was the first to report and showed that the short-acting GLP-1 receptor agonist lixisenatide had no impact on MACEs in 6068 patients after an acute coronary syndrome.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [224]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“No increased risk of heart failure hospitalization has been identi fi ed in the cardiovascular outcomes trials of the GLP-1 receptor agonists lixisenatide, liraglutide, semaglutide, exenatide once-weekly, albiglutide, or dulaglutide compared with placebo ( Table 10.3 B ) (203,204,207 -209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“However, two GLP-1 analogues tested in two studies demonstrated no advantage in influencing cardiovascular outcome.278,279”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [279]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
In the citing paper
“In these trials, GLP-1 receptor agonists had a neutral effect on the risk for HF hospitalization.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,016
Wilding, J. P. H., Godec, T. R., Khunti, K., Pocock, S., Fox, R. A., Smeeth, L. L., Clauson, P., Fenici, P., Hammar, N., & Medina, J. (2018) · BMC Medicine · doi:10.1186/s12916-018-1085-8 · Cited by 50
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 54
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Xu, Y., Fu, E. L., Clase, C. M., Mazhar, F., Jardine, M., & Carrero, J. J. (2021) · Kidney International · doi:10.1016/j.kint.2021.10.033 · Cited by 50
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 60
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
(2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.02.006 · Cited by 49
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 49
Cardiometabolic Syndrome and Increased Risk of Heart Failure
von Bibra, H., Paulus, W., & Sutton, M. S. J. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0298-4 · Cited by 47
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 51
Liu, Y., Zhang, X., Chai, S., Zhao, X., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1534365 · Cited by 49
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 49
Thein, D., Christiansen, M. N., Mogensen, U. M., Bundgaard, J. S., Rørth, R., Madelaire, C., Fosbøl, E. L., Schou, M., Torp-Pedersen, C. T., Gislason, G., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01078-5 · Cited by 48
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Perreault, L., Rodbard, H. W., Valentine, V., & Johnson, E. L. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0868-9 · Cited by 47
Recent advances in diabetes treatments and their perioperative implications
Kuzulugil, D., Papeix, G., Luu, J., & Kerridge, R. K. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000735 · Cited by 49
Jain, A., Ali, A., Martínez, J. J. G., HRAMIAK, I. M., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 49
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 47
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 50
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Jain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00984-x · Cited by 47
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 50
Zhang, Y., Chen, G., Wang, W., Yang, D., Zhu, D., & Jing, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117338 · Cited by 50
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 51
Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 61
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 47
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts
Birkenfeld, A. L., Jordan, J., Dworak, M., Merkel, T., & Burnstock, G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.015 · Cited by 46
Funck, K. L., Knudsen, J. S., Hansen, T. K., Thomsen, R. W., & Grove, E. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14245 · Cited by 45
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 44
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 48
Avilés, B., Soler, M. J., Perez-Belmonte, L. M., Jiménez-Millán, A., Rivas‐Ruiz, F., & de Lucas, M. D. G. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac096 · Cited by 51
Lin, Y., Wang, T.-H., Tsai, M., Wu, V. C., Tseng, C.-J., Lin, M., Li, Y., Chang, C., Chou, T., Tsai, T., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01793-9 · Cited by 55
Effects of GLP-1 receptor agonists on neurological complications of diabetes
García‐Casares, N., González-González, G., Cosme, C. D. L. C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., Narváez, M., Barbancho, M. Á., García-Arnés, J. A., & Tinahones, F. J. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09807-3 · Cited by 52
Mima, A., Nomura, A., & Fujii, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115032 · Cited by 48
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01118-6 · Cited by 48
Krisanapan, P., Suppadungsuk, S., Sanpawithayakul, K., Thongprayoon, C., Pattharanitima, P., Tangpanithandee, S., Mao, M. A., Miao, J., & Cheungpasitporn, W. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae018 · Cited by 47
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 46
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 47
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
Kramer, C. K., Ye, C., Campbell, S., & Retnakaran, R. R. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.021 · Cited by 46
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 48
Lim, S. K., Oh, T. J., Dawson, J., & Sattar, N. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 48
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 45
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 46
D’Andrea, E., Kesselheim, A. S., Franklin, J. M., Jung, E. H., Hey, S. P., & Patorno, E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01133-1 · Cited by 46
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 45
Kawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109146 · Cited by 46
Wei, J., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910256 · Cited by 44
Branch, K. R. H., Dagenais, G. R., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Jansky, P., Lakshmanan, M., Lanas, F., Leiter, L. A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2670 · Cited by 41
Self-citationWei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 48
Wu, S., Lu, W., Chen, Z., Dai, Y., Chen, K., & Zhang, S. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00970-2 · Cited by 49
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 46
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 47
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 44
Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A. J., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 46
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 44
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
Mima, A., Gotoda, H., Lee, R., Murakami, A., Akai, R., & Lee, S. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100236 · Cited by 43
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 43
Medication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4288-1 · Cited by 45
Fadini, G. P., Sarangdhar, M., & Avogaro, A. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000475 · Cited by 44
Barkas, F., Elisaf, M., & Milionis, H. J. (2019) · European Journal of Neurology · doi:10.1111/ene.13905 · Cited by 43
Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J. (2019) · Diabetic Medicine · doi:10.1111/dme.13898 · Cited by 48
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 48
Hunt, B., Malkin, S. J. P., Moes, R. G. J., Huisman, E. L., Vandebrouck, T., & Wolffenbuttel, B. H. R. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000705 · Cited by 43
Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Grover, A., Sharma, K., Gautam, S., Gautam, S., Gulati, M., & Singh, S. K. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666201103144231 · Cited by 47
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
Liu, H., Fu, D., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 45
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 43
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 43
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Lim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 45
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 49
Carbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 44
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
McGuire, D. K., Marx, N., Johansen, O. E., Inzucchi, S. E., Rosenstock, J., & George, J. T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13645 · Cited by 44
Alexander, J. T., Staab, E., Wan, W., Franco, M., Knitter, A., Skandari, M., Bolen, S., Maruthur, N. M., Huang, E. S., Philipson, L., et al. (2021) · Journal of general internal medicine · doi:10.1007/s11606-021-07105-9 · Cited by 42
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 44
Benn, M., Emanuelsson, F., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2021) · Diabetologia · doi:10.1007/s00125-021-05436-0 · Cited by 41
Xu-bin, W., Wei, W., Ding, L., & Liu, S.-Y. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.08.017 · Cited by 41
Wang, A., Tang, H., Zhang, N., & Feng, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109080 · Cited by 44
Banerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad076 · Cited by 49
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 44
Novel therapies for diabetic kidney disease
Cherney, D. Z. I., & Bakris, G. L. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.005 · Cited by 41
Moreira, R. O., Cobas, R. A., & Coelho, R. C. L. A. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0327-4 · Cited by 40
Seferović, J. P., Bentley–Lewis, R., Claggett, B. L., Díaz, R., Gerstein, H. C., Køber, L., Lawson, F. C., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1631263 · Cited by 41
Self-citationHupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Trevisan, M., Fu, E. L., Szummer, K. E., Norhammar, A., Lundman, P., Wanner, C., Sjölander, A., Jernberg, T., & Carrero, J. J. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa004 · Cited by 43
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Yami, M. S. A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01070-z · Cited by 45
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 43
Janež, A., Muzurović, E. M., Stoian, A. P., Haluzı́k, M., Guja, C., Czupryniak, L., Duvnjak, L. S., Lalic, N. M., Tankova, T. I., Bogdański, P., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.017 · Cited by 42
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
Yoshiji, S., Minamino, H., Tanaka, D., Yamane, S., Harada, N., & Inagaki, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14666 · Cited by 40
Greco, C., Santi, D., Brigante, G., Pacchioni, C., & Simoni, M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0314 · Cited by 41
Metadata
- Authors
- Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Solomon, S. D., & Tardif, J.-C.
- Affiliations
- Brigham and Women's Hospital (US)
- Stavanger University Hospital (NO)
- McMaster University (CA)
- Copenhagen University Hospital (DK)
- Sanofi (United States) (US)
- University of Zurich (CH)
- University of Washington Medical Center (US)
- Oregon Health & Science University (US)
- Montreal Heart Institute (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-03
- Volume
- 373
- Issue
- 23
- Pages
- 2247-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282578582
- Cited by
- 2,409
- References
- 38
- Citations by year
- 2026: 136 · 2025: 175 · 2024: 182 · 2023: 165 · 2022: 191 · 2021: 250 · 2020: 281 · 2019: 251 · 2018: 290 · 2017: 278 · 2016: 202 · 2015: 4
- FWCI
- 224.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- lixisenatide, type 2 diabetes, acute coronary syndrome, myocardial infarction, unstable angina, GLP-1 receptor agonists, cardiovascular outcomes, non-inferiority, major adverse cardiovascular events, heart failure hospitalization, serious adverse events, hypoglycemia, pancreatitis, pancreatic neoplasms, allergic reactions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Peptides, Proportional Hazards Models, Treatment Failure, Kaplan-Meier Estimate, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
